Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 1:47 PM
Ignite Modification Date:
2025-12-24 @ 1:47 PM
NCT ID:
NCT04775095
Eligibility Criteria:
Inclusion Criteria:
* Patients with histologically or cytologically confirmed extensive stage NSCLC
* Presence of BRAF V 600 E or non E mutation diagnosed on tumor sample and/or on liquid biopsy (co mutations allowed) between 01/01/2016 and 31/12/2019
* Patients who received at least one dose of treatment with dabrafenib-trametinib combination (whatever the treatment line)
* NSCLC BRAF V600 patients who have not received the dabrafenib-trametinib combination will be included for the collection of clinical and demographic data, treatments received and OS
* Patients who were informed about the study and do not refused for their data to be collected and used
* Age \> 18 years
Exclusion Criteria:
* Patients harboring a non V600 BRAF mutation
* Patients enrolled in a clinical trial assessing treatment with dabrafenib-trametinib combination
* Explicit refusal by the patient to collect his or her data
* Patients under curatorship or guardianship
* Unable to obtain data collection
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04775095
Study Brief:
Protocol Section:
NCT04775095